'Game-changing’ Alzheimer’s drug lecenemab rejected by EU

“This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," explains Professor Bart De Strooper (UCL Queen Square Institute of Neurology).

Listen: BBC Radio 4 ‘Today’ (from 26 mins 10 secs), Read: The Sun, Telegraph (£), Yahoo! News, Japan Times, Free Malaysia Today